Health

Aurora Spine Launches New Biologics Portfolio

New Aurora Biologics Division Establishes Aurora Spine as a Vertically Integrated Source for Spinal Implants and Biologics October 27, 2025…

4 months ago

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor…

4 months ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced…

4 months ago

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…

4 months ago

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

October 26, 2025 19:15 ET  | Source: Vivani Medical, Inc. ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical,…

4 months ago

Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…

4 months ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…

4 months ago

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

October 25, 2025 11:01 ET  | Source: Cullinan Therapeutics, Inc. CLN-978 led to rapid and deep B cell depletion in…

4 months ago

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…

4 months ago

Aletheia Capital Endeavours Launches RepIntel, a Campaign-Grade Platform to Accelerate Global Access to Therapies

October 24, 2025 23:37 ET  | Source: RepIntel. New York, New York, USA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aletheia…

4 months ago